NL-OMON51937尚未招募不适用
Magnetic resonance imaging for phenotyping and accurate Monitoring of Interstitial Lung Disease: the M-ILD study - M-ILD
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Multidisciplinary diagnosis of PF-ILD (progressive fibrotic ILD group
- •including IPF) OR inflammatory ILD (including idiopathic NSIP, ILD related to
- •connective tissue disease or with autoimmune features or chronic
- •hypersensitivity pneumonitis (IGr).
- •- Informed consent
- •- About to start treatment for their ILD. Each patient will be treated as
- •decided in the MDT according to standard clinical practice. PF-ILD and IPF
- •group are usually treated with anti-fibrotic drugs (nintedanib or pirfenidone).
- •The I-ILD group are treated with anti-inflammatory therapy, such as prednisone,
- •mycophenolate mofetil, azathioprine, rituximab.
- •Additional inclusion criteria for subgroup of ILD patients who undergo FDG
- •PF-ILD group:
- •- Patients of PF-ILD group with sign of disease activity as indicated by PFT
- •and symptoms (dyspnea, exercise capacity, cough)
- •I-ILD group:
- •- Patients of I-ILD group with sign of disease activity as indicated by and
- •symptoms (dyspnea, exercise capacity, cough)
排除标准
- •- Contra-indications or inability to undergo MRI (i.e. claustrophobia.)
- •- Current lung infection (according to treating physician)
- •- Respiratory distress at rest despite oxygen
- •- Contra-indication to use gadolinium contrast (severe renal insufficiency,
- •estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2)(28)
- •- Previous allergic reaction to gadolinium or iodinated contrast media
- •- Acute ILD exacerbations at baseline
- •- High flow chronic oxygen need(respiratory distress at rest despite oxygen)
- •- Lung cancer at baseline
- •- For PF-ILD group: previous treatment with anti-fibrotic medications
- •- For I-ILD group: previous treatment with anti-inflammatory medications
- •Additional exclusion criteria for subgroup of ILD patients who undergo FDG
- •PF-ILD group:
- •- Ongoing treatment with anti-fibrotic modulators at baseline
- •I-ILD group:
- •- Ongoing treatment with anti-inflammatory and/or immunomodulators at baseline
研究者
相似试验
已完成
不适用
Diagnostic use of magnetic resonance imaging and magnetic resonance arthrography for intra-articular pathologies of the hip joint – how often reasonable?OPS-Codes 3-805, 3-806, 3-826, 3-82a in combination with ICD M00.95, M13.15, M16.0, M16.1, M16.2, M16.3, M16.4, M16.5, M16.6, M16.7, M16.9, M24.05, M24.15, M24.25, M24.85, M25.55, M25.75, M65.95, M67.45, M85.45, M87.05, M87.15, M87.85, M94.85, M94.95, M99.85, M99.95, S79.8DRKS00011850KRH Klinikum Agnes Karll Laatzen203
已完成
不适用
Markers of Aggressive Local Therapy In Newly diagnosed GlioblastomasGlioblastomasMalignant neoplasm of brainCancerISRCTN62033854Cambridge University Hospitals NHS Foundation Trust (UK)145
已完成
不适用
se of Advanced Magnetic Resonance Imaging (MRI)- a neuroimaging modality- for predicting functional outcome in severe traumatic brain injuryCTRI/2019/04/018800IMHANS intramural funding32
招募中
不适用
Magnetic Resonance Imaging for lesion visualization after catheter ablation for treatment of atrial fibrillatio10007521paroxysmal atrial fibrillationNL-OMON54655HagaZiekenhuis96
已完成
不适用
Development of novel magnetic resonance imaging (MRI) techniques for neurological applicationsTopic: NeurologicalSubtopic: Neurological (all Subtopics)Disease: Nervous system disordersNervous System DiseasesNeurological screeningISRCTN13036842niversity College London (UCL) (UK)150